Gobivaz Biosimilar Earns EEA Approval, Expanding Access to Anti-TNF Therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
Dateline – November 17 2025 | Minneapolis & Miami PetVivo Holdings, Inc. announced that its exclusive AI-technology partner, Digital...
